Login to Your Account



Pharma: Clinic Roundup


Thursday, June 21, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the American Heart Journal published the design of the RE-ALIGN study, a Phase II trial aimed at evaluating the safety and pharmacokinetics of oral Pradaxa (dabigitran etexilate) in patients after heart valve replacement.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription